Purpose There is still scarce data on SARS-CoV-2 infection in patients with Inborn Errors of Immunity (IEI) and many unresolved questions. We aimed to describe the clinical outcome of SARS-CoV-2 infection in Brazilian IEI patients and identify factors influencing the infection. Methods We did a cross-sectional, multicenter study that included patients of any age affected by IEI and SARS-CoV-2 infection. The variables studied were sex, age, type of IEI, comorbidities (number and type), treatment in use for IEI, clinical manifestations and severity of SARS-CoV-2 infection. Results 121 patients were included: 55.4% female, ages from six months to 74 yo (median age = 25.1 yo). Most patients had predominantly antibody deficiency (n = 53). The infection was mostly asymptomatic (n = 21) and mild (n = 66), and one child had multisystem inflammatory syndrome (MIS-C). We could not observe sex-related susceptibility, and there was a weak correlation between age and severity of infection. The number of comorbidities was higher in severe cases, particularly bronchiectasis and cardiopathy. There were no severe cases in hereditary angioedema patients. Six patients aged 2 to 74 years died, three of them with antibody deficiency. Conclusion The outcome was mild in most patients, but the Case Fatality Ratio was higher than in the general population. However, the type of IEI was not a determining factor for severity, except for complement deficiencies linked to milder COVID-19. The severity of SARS-CoV-2 infection seems to be more related to older age, a higher number of comorbidities and type of comorbidities (bronchiectasis and cardiopathy).
A detecção precoce de problemas relacionados com o desenvolvimento da criança é um desafio para a Saúde Pública e principalmente para o pediatra que tem no binômio crescimento-desenvolvimento o eixo de sua especialidade. Na maioria das vezes, o pediatra é o primeiro profissional a ser procurado pelas famílias em busca do diagnóstico dessas crianças nos primeiros cinco anos de vida 1 .O fato de não se ter um instrumento padronizado dificulta a avaliação do desenvolvimento, tornando-a quase inexeqüível. Isso tem contribuído para que alterações no desenvolvimento passem despercebidas, só se tornando evidentes muito tarde, quando a criança ingressa no Ensino Fundamental.As escalas utilizadas na avaliação do desenvolvimento, em sua maioria se baseiam no amadurecimento que é percebido através da aquisição de novas habilidades da criança ao longo do tempo, o qual pode ser observado e acompanhado, porém não pode ser medido com a precisão desejável. Não existe uma medida quantitativa para o desenvolvimento, porém pode-se especificar níveis e graus de desenvolvimento em termos de amadurecimento 2 .Na avaliação de grande número de crianças, a rapidez e o baixo custo são essenciais, requerendo a utilização de instrumento de fácil aplicabilidade, em qualquer nível de atendimento, que
Purpose: There is still scarce data on SARS-CoV-2 infection in patients with Inborn Errors of Immunity (IEI) and many questions. We aimed to describe the clinical outcome of SARS-CoV-2 infection in Brazilian IEI patients and to identify factors influencing the outcome of infection.Methods: We did a cross-sectional, multicenter study that included patients of any age affected by IEI and SARS-CoV-2 infection. The variables studied were sex, age, type of IEI, comorbidities (number and type), treatment in use for IEI, clinical manifestations and severity of SARS-CoV-2 infection. Results: 121 patients were included: 55.4% female, ages from six months to 74 yo (median age = 25.1 yo). Most patients had predominantly antibody deficiency (n=53). The infection presented mostly as asymptomatic (n=21) and mild (n=66), and one child had multisystem inflammatory syndrome (MIS-C). We could not observe sex related susceptibility and observed a weak correlation between age and severity of infection. The number of comorbidities was higher in severe cases, particularly bronchiectasis and cardiopathy. There were no severe cases in hereditary angioedema patients. Six patients aged 2 to 74 years died, three of them with antibody deficiency. Conclusion: The outcome was mild in most patients, but the Case Fatality Ratio was higher than in the general population. Patients with complement deficiencies had milder COVID-19. However, the type of IEI was not a determining factor for severity. The severity of SARS-CoV-2 infection seems to be more related to older age, higher number of comorbidities and type of comorbidities (bronchiectasis and cardiopathy).
We evaluated 22 paired maternal and cord sera regarding the presence of IgG and IgG subclasses against purified Escherichia coli LPS O6, O16 and O111 employing ELISA for titre and avidity analysis, isoelectric focusing associated with affinity-blotting for spectrotypic analysis, and the Western-blotting technique for recognition of the various bands in lipopolysaccharide (LPS). Levels of anti-LPS IgG antibodies in cord sera were equivalent to their respective maternal sera, showing a significant correlation (P < 0.0001). IgG1 antibody levels were higher in cord sera than in maternal sera (P < 0.005 for anti-O111, P < 0.05 for anti-O16 and P < 0.02 for anti-O6). Cord IgG2 antibody levels were not different from the maternal levels (P > 0.1). The levels of IgG3 and IgG4 were undetectable. The avidity of anti-O6 and anti-O111 IgG in 10 cord sera showed an extremely significant correlation with maternal antibody avidity (P < 0.0001). Identical patterns of recognition were found in the paired samples analysed by Western blotting. Most of the serum samples recognized the O-repetitive chains and also the region corresponding to core and lipid A. Although the antibody spectrotypes varied among individuals, paired cord and maternal serum samples showed identical patterns. Our findings suggest the occurrence of placental transfer of IgG antibodies against LPS O6, O16 and O111, mainly involving the IgG1 or IgG2 subclasses.
There is a lack of medical awareness concerning PIDs, even among paediatricians, who have been targeted with PID educational programmes in recent years in Brazil. An increase in awareness with regard to these disorders within the medical community is an important step towards improving recognition and treatment of PIDs.
66,337 exams were conducted with population coverage of less than 70%. The prevalence of phenylketonuria was 1:33,068 live births and of congenital hypothyroidism was 1:9,448 live births. Only 22% of the samples were collected at the recommended ag, and most of the samples were collected between the ages of 8 and 30 days. The median age at collection was 12 days. It was observed that the service had difficulties in recalling suspected cases and financial difficulties in obtaining laboratorial reagents. Conclusions: The age at the time of collection and the delay at the diagnostic confirmation stage were the principal reasons for the delay in the initiation of treatment of the cases detected by the service. Arq Bras Endocrinol Metab. 2009;53(4):446-52. KeywordsCongenital hypothyroidism; phenylketonuria; neonatal screening; program evaluation InTRoDução A fenilcetonúria (PKU) é um erro inato no metabolismo do aminoácido fenilalanina (FAL). É uma doença genética, causada por uma mutação no gene que codifica a enzima, a fenilalanina hidroxilase, que é ativada no fígado e responde pela transformação da fenilalanina em tirosina (1,2). A elevação da fenilalanina no sangue permite a sua passagem em quantidade excessiva
The PSAEFI system proved useful for monitoring DTwP-Hib vaccine safety. We recommended the incorporation of new methodologies, such the use of sentinel cities/hospitals and computerized immunization registries in order to increase its sensitivity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.